Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024
Anixa Biosciences (NASDAQ: ANIX) announced its upcoming presentation at the Sidoti Micro-Cap Virtual Conference on November 14, 2024, at 1:00pm ET. Chairman and CEO Dr. Amit Kumar will present company updates and clinical program developments. The presentation follows the release of latest breast cancer clinical trial data scheduled for November 8, 2024.
Dr. Kumar will also provide updates on their CAR-T trial for recurrent and resistant ovarian cancer patients. Both trials are reportedly producing positive results that exceed expectations. The conference offers 1x1 meetings open to all registered investors.
Anixa Biosciences (NASDAQ: ANIX) ha annunciato la sua prossima presentazione al Sidoti Micro-Cap Virtual Conference il 14 novembre 2024, alle 13:00 ET. Il presidente e CEO, Dr. Amit Kumar, presenterà aggiornamenti sull'azienda e sviluppi del programma clinico. La presentazione segue il rilascio dei dati più recenti sui trial clinici per il cancro al seno, previsto per l'8 novembre 2024.
Il Dr. Kumar fornirà anche aggiornamenti sul loro trial CAR-T per pazienti con cancro ovarico recidivante e resistente. Entrambi i trial stanno producendo risultati positivi che superano le aspettative. La conferenza offre incontri 1x1 aperti a tutti gli investitori registrati.
Anixa Biosciences (NASDAQ: ANIX) anunció su próxima presentación en la Sidoti Micro-Cap Virtual Conference el 14 de noviembre de 2024, a la 1:00 p.m. ET. El presidente y CEO, Dr. Amit Kumar, presentará actualizaciones sobre la empresa y los desarrollos del programa clínico. La presentación sigue a la publicación de los últimos datos de ensayos clínicos sobre el cáncer de mama programados para el 8 de noviembre de 2024.
El Dr. Kumar también proporcionará actualizaciones sobre su ensayo CAR-T para pacientes con cáncer de ovario recurrente y resistente. Ambos ensayos están produciendo resultados positivos que superan las expectativas. La conferencia ofrece reuniones 1x1 abiertas a todos los inversores registrados.
Anixa Biosciences (나스닥: ANIX)는 2024년 11월 14일 오후 1시(동부 표준시)에 Sidoti Micro-Cap Virtual Conference에서 발표할 예정이라고 발표했습니다. 회장 겸 CEO인 Dr. Amit Kumar가 회사의 업데이트와 임상 프로그램 개발에 대해 발표할 것입니다. 이 발표는 2024년 11월 8일로 예정된 최신 유방암 임상시험 데이터 발표에 이어 진행됩니다.
Dr. Kumar는 재발성 및 내성 난소암 환자를 위한 CAR-T 시험에 대한 업데이트도 제공할 것입니다. 두 가지 시험 모두 예상 이상의 긍정적인 결과를 내고 있는 것으로 전해졌습니다. 이번 회의는 모든 등록된 투자자에게 열려 있는 1x1 미팅을 제공합니다.
Anixa Biosciences (NASDAQ: ANIX) a annoncé sa prochaine présentation à la Sidoti Micro-Cap Virtual Conference le 14 novembre 2024 à 13h00 ET. Le président et PDG, Dr. Amit Kumar, présentera des mises à jour sur l'entreprise et les développements du programme clinique. La présentation fait suite à la publication des dernières données des essais cliniques sur le cancer du sein, prévue pour le 8 novembre 2024.
Le Dr. Kumar fournira également des mises à jour sur leur essai CAR-T pour les patientes ayant un cancer de l'ovaire récurrent et résistant. Les deux essais produisent des résultats positifs qui dépassent les attentes. La conférence offre des réunions individuelles ouvertes à tous les investisseurs enregistrés.
Anixa Biosciences (NASDAQ: ANIX) hat seine bevorstehende Präsentation auf der Sidoti Micro-Cap Virtual Conference am 14. November 2024 um 13:00 Uhr ET angekündigt. Der Vorsitzende und CEO Dr. Amit Kumar wird Unternehmensupdates und Entwicklungen im klinischen Programm vorstellen. Die Präsentation erfolgt nach der Veröffentlichung der neuesten Daten zu klinischen Studien über Brustkrebs, die für den 8. November 2024 geplant sind.
Dr. Kumar wird auch Updates zu ihrem CAR-T-Test für wiederkehrende und resistente Ovarialkrebspatienten geben. Beide Studien sollen positive Ergebnisse liefern, die die Erwartungen übertreffen. Die Konferenz bietet 1x1-Meetings, die allen registrierten Investoren offenstehen.
- None.
- None.
Conference details:
Presentation: Thursday, November 14, 2024, at 1:00pm ET
Presentation link: Click here to register; available via Zoom
Conference registration: Available on the conference website
1x1 meetings: Open to all investors upon conference registration
Dr. Kumar stated, "We are pleased to present at this conference, shortly after release of the most up-to-date data from our breast cancer clinical trial, which will occur on November 8, 2024. We will also provide updates to our CAR-T trial for recurrent and resistant ovarian cancer patients. Both trials are producing very positive results, exceeding all of our expectations, and we look forward to providing an update."
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content:https://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-sidoti-micro-cap-virtual-conference-on-november-13--14-2024-302292348.html
SOURCE Anixa Biosciences, Inc.
FAQ
When is Anixa Biosciences (ANIX) presenting at the Sidoti Micro-Cap Conference?
What clinical trials will Anixa Biosciences (ANIX) discuss at the Sidoti Conference?
When will Anixa Biosciences (ANIX) release new breast cancer trial data?